Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma ประกาศข้อตกลงว่าด้วยใบอนุญาตเชิงกลยุทธ์และความร่วมมือกับ Bristol Myers Squibb เพื่อพัฒนาและจำหน่าย Novel Bi-Functional Antibody Obexelimab ในญี่ปุ่น เกาหลีใต้ ไต้หวัน สิงคโปร์ ฮ่องกง และออสเตรเลีย

ความร่วมมือดังกล่าวช่วยส่งเสริมวิสัยทัศน์ของ Zenas ที่จะนำยาภูมิคุ้มกันวิทยาที่ใช้นวัตกรรมที่ทันสมัยไปสู่ผู้ป่วยทั่วโลก โดยใช้ความเชี่ยวชาญที่มีมายาวนานของ Bristol Myers Squibb...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma anuncia acuerdo estratégico de licenciamiento y colaboración con Bristol Myers Squibb para desarrollo y comercialización del nuevo anticuerpo bifuncional Obexelimab en Japón, Corea del Sur, Taiwán, Singapur, Hong Kong y Australia

La colaboración amplía la visión de Zenas de llevar fármacos innovadores basados en inmunología a pacientes de todo el mundo utilizando la experiencia de larga data de Bristol Myers Squibb en...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma Fecha Acordo de Licenciamento e Colaboração Estratégica com a Bristol Myers Squibb para Desenvolvimento e Comercialização do Novo Anticorpo Bifuncional Obexelimab no Japão, Coreia do Sul, Taiwan, Cingapura, Hong Kong e Austrália

Colaboração promove a visão da Zenas de oferecer medicamentos inovadores baseados em imunologia para pacientes em todo o mundo, aproveitando a experiência de longa data da Bristol Myers Squibb com...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma, Bristol Myers Squibb과 전략적인 라이선스 및 협업 계약 체결하고 일본, 한국, 대만, 싱가포르, 홍콩, 호주에서 새로운 이기능성 항체 Obexelimab 개발 및 상용화

면역력 관련 질환에 대한 Bristol Myers Squibb의 역사 깊은 전문성 활용해 전 세계 환자들을 위한 Zenas의 혁신적인 면역학 기반 치료제 비전을 선보일 협력 기회 Zenas는 Bristol Myers Squibb 으로부터 선급금 5,000만 달러와 지분 투자 받고 라이선스 허용된 지역에서 성과 기반의 추가 자금과 로열티도 받을 예정 미국...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma Mengumumkan Lisensi Strategis dan Perjanjian Kolaborasi dengan Bristol Myers Squibb untuk Mengembangkan dan Mengomersialkan Antibodi Dwifungsi Baru Obexelimab di Jepang, Korea Selatan, Taiwan, Singapura, Hong Kong, dan Australia

Kolaborasi ini melanjutkan visi Zenas untuk menghadirkan obat-obatan berbasis imunologi yang inovatif kepada pasien di seluruh dunia dengan memanfaatkan keahlian Bristol Myers Squibb yang telah lama...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma gibt strategische Lizenz- und Kooperationsvereinbarung mit Bristol Myers Squibb zur Entwicklung und Vermarktung des neuartigen bifunktionalen Antikörpers Obexelimab in Japan, Südkorea, Taiwan, Singapur, Hongkong und Australien bekannt

Die Zusammenarbeit fördert die Vision von Zenas, Patienten weltweit innovative immunologische Medikamente zur Verfügung zu stellen, indem das Unternehmen die langjährige Expertise von Bristol Myers...
September 05, 2023 10:26 ET | Source: Zenas BioPharma

Zenas BioPharma 宣布与 Bristol Myers Squibb 达成战略许可和合作协议，在日本、韩国、台湾、新加坡、香港和澳大利亚开发新型双功能抗体奥贝利单抗并将其商业化

此次合作进一步推动了 Zenas 的愿景，即利用 Bristol Myers Squibb 在免疫介导疾病方面的长期专业知识，为世界各地的患者带来创新的免疫学药物 Zenas 将从 Bristol Myers Squibb 获得 5,000 万美元的预付现金和股权投资，以及在许可地区的额外潜在里程碑式付款和特许权使用费马萨诸塞州沃尔瑟姆, Sept. 05, 2023 (GLOBE...
September 05, 2023 06:00 ET | Source: Zenas BioPharma

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated...
August 02, 2023 15:20 ET | Source: Zenas BioPharma

Zenas BioPharma, Lancet Rheumatology 학술지에 IgG4 관련 질환(IgG4-RD) 치료를 위한 연구용 의약품 obexelimab의 임상2상 연구 결과 게재

obexelimab, 대부분의 활동성 IgG4-RD 환자에서 기능적 완치 등 신속하고 강력하며 지속적인 임상적 개선 효과 보여 이번 연구 결과는 IgG4-RD 치료는 물론 기타 B세포 매개 자가면역질환 치료 잠재성도 보인 obexelimab의 지속적인 개발을 뒷받침 미국 매사추세츠주 월섬, Aug. 03, 2023 (GLOBE...
August 02, 2023 15:20 ET | Source: Zenas BioPharma

Zenas BioPharma gibt die Veröffentlichung von Daten zu einer Phase-2-Studie mit Obexelimab, einem Prüfpräparat zur Behandlung der IgG4-assoziierten Erkrankung (IgG4-RD), im Fachjournal „The Lancet Rheumatology“ bekannt

Die Studie ergab, dass Obexelimab bei den meisten Patientinnen und Patienten mit aktiver IgG4-RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschließlich einer...